Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Hepatitis C virus (HCV) infection causes significant global mortality, with genotype 1 (GT-1) accounting for 60% of cases.
• Interferon-free direct-acting antiviral therapies represent a significant advancement in HCV treatment.
• The development of novel drug combinations is crucial to combat HCV, particularly for genotype 1 infections.

Purpose of the Study:

• To evaluate the efficacy and safety of a fixed-dose combination tablet (daclatasvir/asunaprevir/beclabuvir, DCV-TRIO) for Hepatitis C virus (HCV) treatment.
• To assess the sustained virologic response rates and tolerability of DCV-TRIO in patients with HCV genotype 1.
• To investigate the genetic barrier to resistance offered by targeting three key viral proteins simultaneously.

Main Methods:

• Phase III clinical trials (UNITY 1, 2, 3, and 4) were conducted to assess DCV-TRIO.
• The study involved treatment-naive patients infected with Hepatitis C virus genotype 1.
• Efficacy was measured by sustained virologic response at 12 weeks post-treatment, and safety was assessed through adverse event monitoring.

Main Results:

• DCV-TRIO demonstrated high sustained virologic responses (SVR12) ranging from 92% to 100% in treatment-naive patients with HCV GT-1.
• The combination therapy was generally well tolerated, with common adverse events including headache, diarrhea, fatigue, and nausea.
• Few treatment discontinuations were attributed to adverse events, indicating a favorable safety profile.

Conclusions:

• DCV-TRIO is a highly effective and well-tolerated interferon-free treatment option for Hepatitis C virus genotype 1.
• The drug combination offers a high genetic barrier to resistance by targeting multiple viral proteins.
• Future research should explore real-world data and the development of similar regimens for other HCV genotypes at reduced costs.